Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
NCT00113971
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG:
epratuzumab
Sponsor
UCB Pharma